Positron Corporation Enters Industry Partnership Agreement with MedAxiom
Positron Corporation (OTC: POSC), a molecular imaging technology company specializing in PET and PET-CT systems, has announced a strategic partnership with MedAxiom, a leading cardiovascular performance solutions provider.
The partnership connects Positron with MedAxiom's extensive network of cardiovascular organizations, physicians, and thought leaders. This collaboration will provide Positron with market intelligence, clinical insights, and collaboration opportunities to support broader adoption of PET-CT technology in cardiovascular care.
MedAxiom's Executive VP Joe Sasson highlighted the rapid growth of Cardiac PET in transforming cardiovascular care, while Positron's President Adel Abdullah emphasized the partnership's potential to expand their user base and accelerate adoption of their imaging solutions.
Positron Corporation (OTC: POSC), una società di tecnologia di imaging molecolare specializzata in sistemi PET e PET-CT, ha annunciato una partnership strategica con MedAxiom, un fornitore leader di soluzioni per la prestazione cardiovascolare.
La partnership collega Positron all'ampia rete di organizzazioni cardiovascolari, medici e leader di pensiero di MedAxiom. Questa collaborazione fornirà a Positron intelligence di mercato, approfondimenti clinici e opportunità di collaborazione per sostenere una più ampia adozione della tecnologia PET-CT nella cura cardiovascolare.
Il vicepresidente esecutivo di MedAxiom, Joe Sasson, ha evidenziato la rapida crescita del Cardiac PET nel trasformare la cura cardiovascolare, mentre il presidente di Positron, Adel Abdullah, ha sottolineato il potenziale della partnership di espandere la loro base utenti e accelerare l'adozione delle loro soluzioni di imaging.
Positron Corporation (OTC: POSC), una empresa de tecnología de imagen molecular especializada en sistemas PET y PET-CT, ha anunciado una asociación estratégica con MedAxiom, un proveedor líder de soluciones de rendimiento cardiovascular.
La asociación conecta a Positron con la amplia red de organizaciones cardiovasculares, médicos y líderes de pensamiento de MedAxiom. Esta colaboración proporcionará a Positron inteligencia de mercado, ideas clínicas y oportunidades de colaboración para apoyar una adopción más amplia de la tecnología PET-CT en el cuidado cardiovascular.
El vicepresidente ejecutivo de MedAxiom, Joe Sasson, destacó el rápido crecimiento de Cardiac PET en la transformación de la atención cardiovascular, mientras que Adel Abdullah, presidente de Positron, enfatizó el potencial de la asociación para ampliar su base de usuarios y acelerar la adopción de sus soluciones de imagen.
Positron Corporation (OTC: POSC), 분자 영상 기술 회사로 PET 및 PET-CT 시스템을 전문으로 하는, MedAxiom과 전략적 제휴를 발표했다. MedAxiom은 심혈관 성능 솔루션의 선도적 공급자이다.
이 파트너십은 Positron을 MedAxiom의 광범위한 심혈관 조직, 의사 및 사고 리더 네트워크와 연결한다. 이 협업은 Positron에 시장 정보, 임상 통찰 및 협력 기회를 제공하여 심혈관 관리에서 PET-CT 기술의 보다 광범위한 도입을 지원할 것이다.
MedAxiom의 Executive VP Joe Sasson은 Cardiac PET가 심혈관 관리 변혁에 빠르게 기여하고 있다고 강조했고, Positron의 사장 Adel Abdullah는 이 파트너십이 사용자 기반을 확장하고 이미징 솔루션의 채택을 가속화할 가능성을 강조했다.
Positron Corporation (OTC: POSC), une société de technologie d'imagerie moléculaire spécialisée dans les systèmes PET et PET-CT, a annoncé un partenariat stratégique avec MedAxiom, un fournisseur leader de solutions de performance cardiovasculaire.
Le partenariat relie Positron au vaste réseau d'organisations cardiovasculaires, de médecins et de leaders d'opinion de MedAxiom. Cette collaboration fournira à Positron des informations sur le marché, des insights cliniques et des opportunités de collaboration pour soutenir une adoption plus large de la technologie PET-CT dans les soins cardiovasculaires.
Le vice-président exécutif de MedAxiom, Joe Sasson, a souligné la croissance rapide du Cardiac PET dans la transformation des soins cardiovasculaires, tandis que le président de Positron, Adel Abdullah, a mis l'accent sur le potentiel du partenariat pour élargir leur base d'utilisateurs et accélérer l'adoption de leurs solutions d'imagerie.
Positron Corporation (OTC: POSC), ein Unternehmen für Molekularbildgebungstechnik mit Spezialisierung auf PET- und PET-CT-Systeme, hat eine strategische Partnerschaft mit MedAxiom, einem führenden Anbieter von Lösungen für vaskuläre Leistungsfähigkeit, bekannt gegeben.
Die Partnerschaft verbindet Positron mit MedAxioms umfangreichem Netzwerk aus kardioVask-Organisationen, Ärzten und Vordenkern. Diese Zusammenarbeit wird Positron Marktintelligenz, klinische Einblicke und Kooperationsmöglichkeiten bieten, um die breitere Einführung der PET-CT-Technologie in der kardiovaskulären Versorgung zu unterstützen.
Der Executive Vice President von MedAxiom, Joe Sasson, hob das schnelle Wachstum von Cardiac PET hervor, das die kardiovaskuläre Versorgung transformiert, während Positrons Präsident Adel Abdullah das Potenzial der Partnerschaft betonte, ihre Benutzerbasis zu erweitern und die Einführung ihrer Bildgebungslösungen zu beschleunigen.
Positron Corporation (OTC: POSC)، شركة تكنولوجيا تصوير جزيئي متخصصة في أنظمة PET و PET-CT، أعلنت عن شراكة استراتيجية مع MedAxiom، مزود حلول الأداء القلبية الوعائية الرائد.
تربط الشراكة Positron بشبكة MedAxiom الواسعة من المؤسسات القلبية الوعائية، والأطباء، وقادة الفكر. ستوفر هذه التعاون لـ Positron معلومات سوقية، ورؤى إكلينيكية، وفرص تعاون لدعم التبني الأوسع لتقنية PET-CT في رعاية القلب والأوعية الدموية.
أبرز نائب رئيس MedAxiom التنفيذي جو سايسون النمو السريع لـ Cardiac PET في تحويل رعاية القلب والأوعية الدموية، بينما أكد رئيس Positron Adel Abdullah إمكانات الشراكة في توسيع قاعدة مستخدميهم وتسريع اعتماد حلول التصوير لديهم.
Positron Corporation (OTC: POSC)，一家专注于PET和PET-CT系统的分子成像技术公司，宣布与MedAxiom建立战略伙伴关系， MedAxiom是领先的心血管性能解决方案提供商。
该伙伴关系将 Positron 与 MedAxiom 的广泛心血管组织、医生和思想领袖网络联系起来。这次合作将为 Positron 提供市场情报、临床洞察和合作机会，以支持PET-CT 技术在心血管护理中的更广泛应用。
MedAxiom 的执行副总裁 Joe Sasson 强调 Cardiac PET 在改变心血管护理方面的快速增长，而 Positron 的总裁 Adel Abdullah 强调该伙伴关系扩大用户群并加速其影像解决方案采用的潜力。
- Access to MedAxiom's extensive network of cardiovascular organizations and physicians
- Partnership provides valuable market intelligence and clinical insights
- Potential for accelerated adoption of PET-CT technology
- Strategic positioning in the growing cardiac PET market
- None.
Buffalo, NY, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging technology company specializing in PET and PET-CT imaging systems and clinical services is pleased to announce a partnership with MedAxiom, the cardiovascular community’s premier source for organizational performance solutions.
MedAxiom is recognized nationwide for its extensive network of physicians, clinicians, and administrators, and for driving innovation and best practices that improve outcomes and performance across cardiovascular medicine.
As a MedAxiom industry partner, Positron is connected to the nation’s leading cardiovascular organizations, gaining valuable insights and exposure that advance the adoption of the PET modality. This collaboration provides unparalleled access to hundreds of organizations and thousands of physicians, clinicians, and thought leaders who are driving advancements in nuclear cardiology. Engagement with the MedAxiom community will provide Positron with market intelligence, clinical insight, and opportunities for collaboration that support broader adoption of PET-CT technology and improved patient care.
"Cardiac PET is transforming cardiovascular care, and its rapid growth shows no signs of slowing,” said Joe Sasson, PhD, MedAxiom’s executive vice president of Ventures and chief commercial officer. “As programs increasingly adopt this advanced diagnostic tool in pursuit of high-quality care, MedAxiom looks forward to partnering with Positron to bring valuable education, innovative solutions, and meaningful operational insights to our community of cardiovascular leaders."
Adel Abdullah, President of Positron, commented, “MedAxiom is a trusted leader in cardiovascular excellence, and we are proud to join such a valuable network. This partnership connects Positron with a community at the forefront of transforming cardiovascular care through the PET modality. It is an exciting time for both Positron and the nuclear cardiology field, and MedAxiom will be a tremendous resource helping us expand our user base and accelerate adoption of our imaging solutions.”
About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's PET and PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com.
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
info@skylineccg.com
FAQ
What is the significance of Positron's (OTC: POSC) partnership with MedAxiom?
How will the MedAxiom partnership benefit Positron Corporation (POSC)?
What is the current state of Cardiac PET technology according to MedAxiom?
Who are the key executives involved in the Positron-MedAxiom partnership?
What type of imaging technology does Positron Corporation (POSC) specialize in?
